R2G AAV Gene Delivery Assay Service

AAVs: A PROMISING VECTOR FOR GENE THERAPY

For diseases that currently have no effective treatments, adeno-associated viruses (AAVs) are a promising vector for gene therapy, whereby these vectors are used to deliver therapeutic genes to specific cell types to treat genetic diseases at their source.

Our Ready-2-Go Assay Service provides a panel of AAV serotypes packaged with a fluorescent reporter and matrixed with a panel of iPSC-derived cell types for you to assess your AAVs' tropisms.

KEY FEATURES

Choose from a panel of human, iPSC-derived cell types

Get comparative assessment of AAV transduction

Only 6-8 weeks from assay to report

Option to bundle R2G Services or transition to Custom Services

Efficacy

Current AAV-based therapies require extremely high doses of AAV. Optimizing the tropism of your AAVs can lower the effective dose and increase efficiency of treatment.

Preferential Uptake

Systemic administration of AAVs often results in AAV accumulation in untargeted organs, instead of delivery to their intended tissue type. Assess the preferential uptake of your AAVs to develop safe, targeted, AAV-based, gene therapies.

Safety & Toxicity

Bundle this service with our Ready-2-Go Cell Health and Neurotoxicity assay services to gain a better understanding of your therapeutics' impact on cell viability.

CHOOSE YOUR CELL TYPES

The use of animal models or immortalized cell lines limits clinical translatability. Avoid species differences with our panel of human, iPSC-derived cell types for a scalable and clinically relevant model.